The detection and identification of bacterial species in clinical samples are crucial for patient management and antibiotic treatment. When culture-based identification methods fail, 16S rRNA gene ...

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...

Next-generation sequencing (NGS) has increased the speed, scale, throughput, and accessibility of sequencing, greatly accelerating genomic research. This progress has been aided by the development of ...

Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip. Prognostic value of ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing (NGS) methods in nonclinical studies to assess the safety risks associated ...

Indexes vary greatly and perform differently in different conditions. Some designs are predisposed to dimerization, while others are optimized at certain concentrations, and some will not be optimized ...

Next-generation sequencing (NGS) has revolutionized genomics, empowering scientists with a powerful tool to sequence millions of DNA fragments at once. This transformative technology has increased the ...

Advances in next-generation sequencing (NGS) have propelled genomics research to new heights. With the introduction of new sequencing platforms such as Element Biosciences’ AVITI and Ultima Genomics’ ...

Prior to the advent of the Next Generation Sequencing (NGS) and Third Generation Sequencing (TGS) platforms, the analysis of microbial compositions relied on traditional bacteriological procedures.

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.